Intervet/Schering-Plough Animal Health company develops, manufactures, and markets veterinary vaccines and pharmaceutical products. Its product portfolio includes vaccines for use in pets, livestock, poultry and aquaculture; treatment lines include antiparasitics, anti-infectives, and endocrine products. Intervet/Schering-Plough Animal Health also develops feed additives and animal productivity enhancers. Intervet/Schering-Plough Animal Health operates in more than 50 countries and sells its products around the world. Intervet/Schering-Plough Animal Health company is a subsidiary of Merck.

Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Boehringer Ingelheim Pharmaceuticals brings a little German drugmaking know-how to the USA. The firm is the pharmaceuticals unit of Boehringer Ingelheim Corporation, which is the US headquarters of Germany's Boehringer Ingelheim. It sells a range of prescription and over-the-counter drugs in the US market, including respiratory treatments Spiriva and Atrovent; high blood pressure medication Micardis; enlarged prostate treatment Flomax; Parkinson's disease drug Mirapex; and HIV/AIDS products Aptivus and Viramune. It is also an R&D center for Boehringer Ingelheim, specializing in immunology, inflammatory conditions, and cardiovascular disease.

William Ransom & Son plc is a United Kingdom-based company engaged in the supply of branded natural health products, vitamins and food supplements, the manufacture of pharmaceutical products and the extraction of plant material for the pharmaceutical, food and beverage industries. The Company operates in three divisions: consumer healthcare, pharmaceutical and natural products. Consumer healthcare includes the sale of consumer-branded healthcare products. The pharmaceutical division includes the manufacture of its own Medicines and Healthcare Products Regulatory Agency (MHRA)-licensed products, as well as pharmaceuticals and over-the-counter products for third parties. The natural products division includes the manufacture of botanical extracts used as ingredients by the pharmaceutical division and sold to third parties.

Eurand N.V. company was formerly known as Eurand B.V. Eurand N.V. was incorporated in 1984 and is based in Amsterdam, the Netherlands. Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body to increase efficacy or to reduce side effects; Tastemasking/ODTs technologies to increase patient compliance through more convenient dosage forms, such as orally disintegrating tablets and taste-masked drugs; bioavailability enhancement technologies to improve drug absorption; and drug conjugation technologies to extend drug half-life and to target specific organs or other biological targets, such as tumors. Its technologies are used for applications in drug products used for various therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition, and respiratory.Eurand company offers EUR-1037, as an over-the-counter sleep-aid; EUR-1025, an oral formulation of ondansetron, an anti-emetic prescribed to prevent nausea and vomiting; and EUR-1073, an enteric coated, controlled release formulation of beclomethasone diproprionate for the treatment of inflammatory bowel disease. It products also include Zentase, also known as EUR-1008, a porcine-derived proprietary enzyme replacement product for the treatment of exocrine pancreatic insufficiency, which has completed Phase III clinical trials; Amrix, a sustained release formulation of cyclobenzaprine hydrochloride, used as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute and painful musculoskeletal conditions; and products and services to the cystic fibrosis community.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

Phytopharm is hunting for better drugs. The company struck a deal with Unilever in late 2004 to develop a slimming aid based on the African cactus hoodia, used in Africa to stave off hunger during hunting trips. This developer of botanical pharmaceuticals concentrates on four drug-discovery areas -- obesity and metabolic disease, neurodegeneration, inflammation, and dermatology. In addition, Phytopharm markets two veterinary dermatology products in the UK.

CyDex Pharmaceuticals, Inc. company was founded in 1993 and is based in Lenexa, Kansas. CyDex Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of drugs specifically designed to address limitations of current therapies. It develops a portfolio of product candidates utilizing its drug formulation technology using Captisol, a group of cyclodextrins. The company’s products include Geodon IM and Abilify Injection IM for bipolar disorder/schizophrenia; Vfend IV for antifungal; and Cerenia for canine motion sickness. It also develops Fosphenytoin IV and IM for status epilepticus; Melphalan IV for multiple myeloma; Topiramate IV for epilepsy; Amiodarone IV for arrhythmia; Budesonide Solution Inhalation for asthma; Clopidogrel IV for atherothrombosis; and Budesonide/Azelastine Nasal Spray for allergic rhinitis. In addition, the company out license its technology to third parties for use in the development of their products. CyDex Pharmaceuticals, Inc. was formerly known as CyDex, Inc. and it changed its name in November 2007.

Nature's Way Holding Company manufactures and markets nutritional supplements and other OTC products which are sold with the Enzymatic Therapy, Nature's Way, and Remifemin labels through natural foods retailers and mass market retailers in the US. Its products are aimed to alleviate everything from sleeplessness to hot flashes and are distributed throughout the US and to more than 40 other countries. Its Integrative Therapeutics and Vitaline brands are sold through healthcare practitioners' offices. The company is a unit of German firm Dr. Willmar Schwabe Pharmaceuticals.

Surface Logix creates new drugs by tweaking the pharmacokinetic and pharmacodynamic properties of existing drugs and new compounds. Its Pharmacomer Technology improves a drug's solubility and permeability in the body and reduce side effects. It has a pipeline of pre-clinical and clinical candidates in development for treatment of metabolic diseases and hypertension. Its drug candidate SLx-4090 is in clinical trials to test its ability to lower blood lipid levels, reduce triglyceride uptake, and block absorption of other fats. Its SLx-2101 candidate is being investigated for treatment of hypertension and Raynaud's Syndrome.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.